MBX Biosciences, a startup co-founded by Dr. Richard DiMarchi, recently raised $163.2 million in its U.S. initial public offering. The company’s peptides are based on chemistry developed by a research team led by Dr. DiMarchi, Distinguished Professor of Chemistry in the College of Arts and Sciences and a Linda and Jack Gill Chair at the Gill Institute for Neurosciences at IU Bloomington.
DiMarchi founded the company alongside Hawryluk, an IU alumnus, in 2019. It is the eighth biotechnology startup co-founded by DiMarchi and the sixth to successfully transition from venture funding to the next stage of commercialization.
MBX Biosciences, which is headquartered in Carmel, Ind., aims to transform native peptides to innovative therapeutics to improve clinical outcomes and help individuals with endocrine and metabolic diseases, such as hypoparathyroidism and obesity, live healthier lives. The company plans to advance a pipeline of peptide hormone analogs with drug candidates such as MBX 2109, a treatment for chronic hypoparathyroidism, and MBX 4291, an obesity treatment. By taking MBX Biosciences public, the company can further its goal of transforming treatments for endocrine and metabolic diseases through the creation of safe and effective therapeutics.
